GABŁO, Natalia Anna, Vladimír PROCHÁZKA, Z. HLAVSA, I. KISS, J. SROVNAL, Zdeněk KALA and Ondřej SLABÝ. Analýza mikroRNA v krevní plazmě s cílem identifi kovat pacienty s duktálním adenokarcinomem pankreatu mající benefi t z chirurgické resekce (Analysis of blood plasma micrornas to enable identification of patients with pancreatic ductal adenocarcinoma who will benefit from surgical resection). Klinická onkologie. Ambit Media a.s., 2019, vol. 32, No 2019, p. 174-176. ISSN 0862-495X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Analýza mikroRNA v krevní plazmě s cílem identifi kovat pacienty s duktálním adenokarcinomem pankreatu mající benefi t z chirurgické resekce
Name (in English) Analysis of blood plasma micrornas to enable identification of patients with pancreatic ductal adenocarcinoma who will benefit from surgical resection
Authors GABŁO, Natalia Anna (616 Poland, belonging to the institution), Vladimír PROCHÁZKA (203 Czech Republic, belonging to the institution), Z. HLAVSA, I. KISS, J. SROVNAL, Zdeněk KALA (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution).
Edition Klinická onkologie, Ambit Media a.s. 2019, 0862-495X.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14740/19:00108618
Organization unit Central European Institute of Technology
Keywords in English Biomarkers; Tumor; MicroRNAs
Tags rivok
Tags Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 3/4/2020 19:04.
Abstract
Duktální adenokarcinom pankreatu (pancreatic ductal adenocarcinoma – PDAC) je nejčastější maligní onemocnění pankreatu charakterizované extrémně špatnou prognózou z velké části kvůli problému s včasnou diagnózou a nedostatečným pokrokem v personalizaci léčby. Ze všech dostupných léčebných strategií zůstává totální resekce nádoru v jeho časném stadiu jediným prostředkem k dosažení dlouhodobého přežití. Nicméně i radikální chirurgická resekce nemusí v některých případech poskytnout přínos pro přežití pacientů. Vhodný výběr pacientů, kteří budou mít benefit z resekčního výkonu, je proto velice důležitý.
Abstract (in English)
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of pancreas, characterized by extremely poor prognosis largely due to problem with early dia gnosis and lack of progress in personalization of therapy. Of all available treatment strategies, radical surgical resection of the tumour in its early stage remains the only possibility how to reach long-term survival. However, even a technically perfect surgical resection may still not provide a survival benefi t for all PDAC patients. Appropriate selection of patients for surgical resection is one the important medical needs in management of PDAC patients. Material and methods: To this study we enrolled 24 PDAC patients who underwent surgical resection and preoperatively collected their blood plasma specimends. Patients were divided into to two prognostic groups according to their overall survival-12 patients with poor prognosis (median overall survival 10 months) and 12 patients with good prognosis (median overall survival 25 months). Small RNA sequencing technology was applied to screen for microRNAs (miRNA) with diff erential levels between both PDAC patient’s group. cDNA libraries were prepared using QIAseq miRNA Library Kit (Qiaqen) and sequencing by NextSeq500 instrument (Illumina). Results: When miRNA expression profi les of the PDAC patients from good and poor prognostic groups were compared, 61 miRNAs were identifi ed to have signifi cantly diff erent plasma levels between the two groups (p < 0.05). A total of 21 miRNAs showed increased expression and 40 miRNAs showed decreased expression in a group of patients with poor prognosis compared to patients with good prognosis. Conclusion: This study demonstrated diff erences in miRNA expression profiles in preoperative plasma specimens of PDAC patients with short and long overall survival. Our observations indicate that after independent validations plasma miRNAs might become useful bio markers for identifi cation of PDAC patients having clinical benefi t from surgical resection of the tumour.
Links
NV16-31314A, research and development projectName: Identifikace cirkulujících mikroRNA umožňujících prognostickou stratifikaci a selekci pacientů nejvíce profitujících z chirurgické léčby
PrintDisplayed: 4/5/2024 02:39